Can't say for sure since I'm not in this field, but some reddit research led to this:
>Whether acute klotho elevation represents a strategy that can rapidly enhance cognition, motor functions, and/or induce brain resilience is a gap in our knowledge of its therapeutic potential. Here we show that αKL-F, a fragment of the α-klotho protein similar to its secreted form, can acutely improve cognitive and motor functions following peripheral administration. It does so despite apparent impermeability to the blood-brain barrier in young, aging, and hSYN transgenic mice. Further investigation of αKL-F-mediated molecular mechanisms revealed activation of glutamatergic signaling and enhancement of synaptic plasticity.
So the research around klotho may produce something which doesn't actually need to cross the BBB as a retail drug, but on a simultaneous front, we have gene manipulation via CRISPR that would also increase klotho production.
>Whether acute klotho elevation represents a strategy that can rapidly enhance cognition, motor functions, and/or induce brain resilience is a gap in our knowledge of its therapeutic potential. Here we show that αKL-F, a fragment of the α-klotho protein similar to its secreted form, can acutely improve cognitive and motor functions following peripheral administration. It does so despite apparent impermeability to the blood-brain barrier in young, aging, and hSYN transgenic mice. Further investigation of αKL-F-mediated molecular mechanisms revealed activation of glutamatergic signaling and enhancement of synaptic plasticity.
https://www.cell.com/cell-reports/fulltext/S2211-1247(17)309...
So the research around klotho may produce something which doesn't actually need to cross the BBB as a retail drug, but on a simultaneous front, we have gene manipulation via CRISPR that would also increase klotho production.